...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cellular Physiology >Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
【24h】

Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.

机译：在formalin-fixed分析信号通路乳腺癌和石蜡包埋组织揭示了表皮生长因子受体之间的相声,HER2 HER3,和

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the last few years, new approaches and developments in patient-tailored cancer therapies have raised the need to select, more precisely, those patients who will respond to personalized treatments. Therefore, the most efficient way for optimal therapy and patient selection is to provide a tumour-specific protein network portrait prior to treatment. The aim of our study was to monitor protein networks in formalin-fixed and paraffin-embedded (FFPE) breast cancer tissues, with special emphasis on epidermal growth factor receptor 2 (HER2)-mediated signalling pathways, to identify and validate new disease markers. For this purpose we used a recently developed technology to extract full-length proteins from FFPE tissues and analysed 23 molecules involved in HER2-related signalling by reverse phase protein microarray (RPPA) in a series of 106 FFPE breast cancer tissue samples. We found a significant correlation of HER2 with human epidermal growth factor receptor 3 (HER3/erbB3), epidermal growth factor receptor 1 (EGFR/HER1/erbB1) and urokinase plasminogen receptor (uPAR) in routinely used FFPE breast cancer tissues. Thus, targeting HER2, EGFR, HER3 and uPAR together may offer a more efficient treatment option for patients with breast cancer.
机译：在过去的几年中,新的方法和病人个体化癌症治疗的发展提出了需要选择,更准确地说,患者将如何应对个性化治疗方法。最佳治疗和患者选择提供一个肿瘤特异蛋白网络画像前治疗。监控formalin-fixed蛋白质网络吗和石蜡包埋(FFPE)乳腺癌组织,特别强调表皮生长因子受体2 (HER2)介导的信号通路,识别和验证新的疾病标记。最近开发的技术来提取从FFPE组织和完整的蛋白质分析了23 HER2-related所涉及的分子信号通过反相蛋白微阵列(RPPA)在一系列的106 FFPE乳腺癌组织样本。HER2与人类表皮生长的相关性因子受体3 (HER3 / erbB3)表皮生长因子受体1 (EGFR / HER1 / erbB1)和尿激酶纤溶酶原受体(uPAR)物经常使用FFPE乳腺癌组织。表皮生长因子受体,HER3 uPAR可能提供更多患者有效的治疗选择乳腺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号